Valvular & structural heart disease
Outcomes of Transcatheter Aortic Valve Replacement in Patients With Coexisiting Amyloidosis: Mortality, Stroke, and Readmission
Authors' conclusion
This analysis suggests amyloidosis may be associated with a higher thromboembolic risk after TAVR
Study context
- Population
- Hospitalizations for transcatheter aortic valve replacement (TAVR), US Nationwide Readmissions Database, 2016–2019; mean age 79.4 ± 8.4 years
- Participants
- 245,020 hospitalizations
- Exposure
- Amyloidosis vs no amyloidosis in TAVR
- Amyloidosisn = 273
- Outcome
- In-hospital mortality, acute ischemic stroke and 30-day readmission after TAVR
Methodological detailsNationwide Readmissions Database, propensity score-weighted
- Nationwide Readmissions Database
- Propensity score-weighted
Main finding
As reported in the abstract
Amyloidosis
- In-hospital mortality
- 1.8%
- 30-day readmission
- 12.9%
- Acute ischemic stroke
- 6.2%
No amyloidosis
- In-hospital mortality
- 1.5%
- 30-day readmission
- 12.5%
- Acute ischemic stroke
- 1.8%
In-hospital mortality
Amyloidosis1.8%
No amyloidosis1.5%
30-day readmission
Amyloidosis12.9%
No amyloidosis12.5%
Acute ischemic stroke
Amyloidosis6.2%
No amyloidosis1.8%
Amyloidosis vs No amyloidosisEstimate (95% CI)P value
Acute ischemic stroke; propensity score-weighted
OR 3.08(1.41–6.71)
P = 0.005Mortality; propensity score-weighted
OR 0.79(0.28–2.27)
P = 0.66630-day readmission; propensity score-weighted
HR 0.72(0.41–1.25)
P = 0.241Observational data: associations, not effects.
Original publication
Outcomes of Transcatheter Aortic Valve Replacement in Patients With Coexisiting Amyloidosis: Mortality, Stroke, and Readmission. JACC Adv. Published 8 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →